All In Biotech

NDA 022038 · Vertical Pharms

Divigel

Estradiol · Transdermal · Estrogen

Last checked: Nov 20, 2026Latest source record: Feb 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Jun 4, 2007

Approved uses

3

Original approval plus efficacy supplements

Registered trials

1,701

351 Phase 3, 176 recruiting

FAERS reports

47,535

22,781 serious, 925 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ENDOMETRIAL CANCER WITH UNOPPOSED ESTROGEN IN WOMEN WITH A UTERUS There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestogen to estrogen-only therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Perform adequate diagnostic measures, including directed or random endometrial sampling when indicated, to rule out malignancy in menopausal women with abnormal genital bleeding of unknown etiology [see Warnings and Precautions ( 5.2 )]. WARNING: ENDOMETRIAL CANCER WITH UNOPPOSED ESTROGEN IN WOMEN WITH A UTERUS See full prescribing information for complete boxed warning. There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens ( 5.2 )

What it is approved for

From the label in effect Aug 21, 2026.

Estradiol gel is an estrogen indicated for the treatment of moderate to severe vasomotor symptoms due to menopause ( 1.1 ). 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause

Mechanism: Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After...

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • DIVIGEL · ESTRADIOL 0.1% (1.25GM/PACKET) · GEL, TRANSDERMAL · Prescription · TE AB
  • DIVIGEL · ESTRADIOL 0.1% (1GM/PACKET) · GEL, TRANSDERMAL · Prescription · TE AB
  • DIVIGEL · ESTRADIOL 0.1% (0.25GM/PACKET) · GEL, TRANSDERMAL · Prescription · TE AB
  • DIVIGEL · ESTRADIOL 0.1% (0.75GM/PACKET) · GEL, TRANSDERMAL · Prescription · TE AB
  • DIVIGEL · ESTRADIOL 0.1% (0.5GM/PACKET) · GEL, TRANSDERMAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Estradiol" as an intervention, any sponsor and status, largest first.

All 1,701 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,941
  • headache2,924
  • fatigue2,903
  • nausea2,901
  • off label use2,436
  • pain2,096
  • diarrhoea1,967
  • dizziness1,746
  • breast cancer female1,709
  • arthralgia1,656
  • pruritus1,576
  • rash1,553

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004525
2005572
2006402
20071,461
2008430
2009600
2010959
2011851
20121,153
2013923
20141,119
20151,927
20162,370
20172,169
20182,525
20192,933
20202,950
20212,889
20223,132
20233,622
20243,717
20255,267
20265,038

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Divigel (Estradiol)

2024 spending

$623K

Beneficiaries

604

2,356 claims

Per beneficiary

$1,031

$5.26 per unit

View as table
YearSpending
2020$2,211,360
2021$2,772,445
2022$3,027,712
2023$1,071,117
2024$622,606

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,476 on PubMed

Sponsor: Vertical Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.